Related Experiment Video
Updated: Sep 11, 2025
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
Design, Synthesis and Evaluation of 4-Methoxy-1H-[1,2,3]triazolo[4,5-c]quinolines as Highly Potent and Oral Available
Haowen Ma1, Chaoming Huang2, Manzhen Gu1,2
1College of Chemistry and Materials Science, Zhejiang Normal University, no. 688 Yingbin Road, Jinhua, Zhejiang Province 321004, China.
Abstract:
RIOK2 is a promising therapeutic target in cancer due to its pivotal role in tumor progression. Based on our previously identified RIOK2 inhibitor CQ211, we conducted a comprehensive pharmacokinetic optimization campaign, leading to the discovery of CQ3196 as a potent and orally bioavailable RIOK2 inhibitor. CQ3196 demonstrates remarkable RIOK2 binding affinity, with a Kd value of 14 nM, and exhibits potent proliferative inhibitory activities in gastric cancer cell lines. Furthermore, CQ3196 displays favorable PK properties, it achieves an AUC(0-t) value of 3.5 × 103 μg/L·h following oral administration, ensuring sufficient drug exposure for therapeutic efficacy. Additionally, it achieves robust in vivo antitumor efficacy in an HGC-27 gastric cancer xenograft model. Oral administration of CQ3196 at 50 mg/kg resulted in a TGI value of 62.3%, highlighting its strong therapeutic potential. These compelling results underscore CQ3196 as a highly promising candidate for further development in RIOK2-targeted cancer therapy.
